Cencora
COR
$356.94
-0.58%
Cencora, Inc. is one of the three dominant U.S. pharmaceutical wholesalers, sourcing and distributing branded, generic, and specialty drugs to retail chains, independent pharmacies, hospitals, and providers, while also operating higher-margin adjacent businesses including manufacturer commercialization services, global specialty logistics through World Courier, European distribution via Alliance Healthcare, and animal health distribution through MWI. Alongside McKesson and Cardinal Health, Cencora is part of an oligopoly controlling more than 90% of the U.S. pharmaceutical wholesale market, giving it formidable scale, entrenched customer relationships, and deep manufacturer partnerships that function as structural moats. The current investor narrative centers on specialty pharmaceutical growth and margin expansion, reinforced by a Q4 fiscal 2026 earnings and revenue beat, an upbeat fiscal 2027 outlook, and a raised FY2026 EPS guide issued in September, which together have reframed the stock from a low-margin volume story into a higher-quality earnings compounder. Debate now hinges on whether specialty mix shift and international diversification can sustain margin gains against razor-thin industry economics, drug pricing policy risk, and customer concentration among large retail pharmacy chains.…
COR
Cencora
$356.94
Related headlines
Investment Opinion: Should I buy COR Today?
Rating: Buy, with a moderate-conviction, valuation-aware caveat. The core thesis is that Cencora has transitioned from a low-margin volume distributor into a specialty-driven earnings compounder — Q4 FY2026 gross margin of 4.08% versus 3.11% a year ago and gross profit of $3.60 billion versus $2.60 billion on only 5.52% revenue growth — yet the stock still trades at just 16.65x trailing and 16.54x forward earnings. The 12-analyst consensus is 'buy' (10 Buy, 4 Hold, 0 Sell) with a recommendation mean of 1.79 and an average target of $382.42, implying about +6.5% upside from $359.03.
Supporting evidence is broad: revenue grew 5.52% YoY to $88.35 billion in Q4 FY2026 with a consistent multi-quarter cadence ($85.93B, $78.36B, $84.75B, $88.35B), TTM free cash flow of $3.88 billion comfortably covers $116 million of dividends and $481 million of debt repayment, and the negative cash conversion cycle of -12.09 days means suppliers fund working capital. The forward PE of 16.54x is essentially identical to the trailing 16.65x, so the market is not pricing in the EPS growth implied by the raised FY2026 guide and upbeat FY2027 outlook, and the PEG of 0.133 — while noisy given prior-year earnings volatility — reinforces that growth is cheap relative to the multiple. Beta of 0.571 and a 0.82% dividend with a conservative 13.7% payout ratio round out a defensive, cash-generative profile.
Three risks could invalidate the thesis: a gross-margin reversion toward the 3.1% prior-year level (a 41-basis-point compression would erase roughly a tenth of gross profit given the 4.11% gross margin and 1.03% net margin), customer concentration in U.S. Healthcare Solutions ($74.86 billion of $88.35 billion quarterly revenue) with large retail pharmacy chains, and drug pricing policy reform hitting manufacturer services. The rating would upgrade to a stronger Buy if gross margins hold above 4.2% through FY2027 or if the multiple stays below 17x while EPS guidance is raised again; it would downgrade to Hold if gross margin falls below 3.8% for two consecutive quarters or if a major retail customer renegotiates volume. Net verdict: fairly valued to modestly undervalued relative to its own history (16.65x versus 27.60x at Q4 FY2026 and 17.91x at Q3) and cheap in absolute terms, but the +6.5% average-target upside and -8% downside to the $330 low target mean the risk/reward is positive rather than compelling.
Sign up to view all
COR 12-Month Price Forecast
The forward view is constructive but tempered by how much of the near-term optimism is already reflected in the price after a 39.32% six-month rally. The margin expansion story is genuine and multi-quarter — Q3 FY2026 gross margin was 4.26% and Q4 was 4.08% versus 3.11% a year earlier — and at 16.65x trailing earnings the stock is cheap relative to its own 27.60x historical multiple, leaving room for either earnings compounding or modest re-rating. The main constraint is the +6.5% upside to the $382.42 average target and the -8% downside to the $330 low target, a positive but not asymmetric risk/reward. I would upgrade to high confidence if gross margins hold above 4.2% through two more quarters with FY2027 guidance raised, and I would downgrade to neutral if gross margin falls below 3.8% or if a major retail customer renegotiates volume.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Cencora's 12-month outlook, with a consensus price target around $382.42 and implied upside of +7.1% versus the current price.
Average Target
$382.42
14 analysts
Implied Upside
+7.1%
vs. current price
Analyst Count
14
covering this stock
Price Range
$330 - $414
Analyst target range
Coverage is solid for a large-cap distributor, with 12 analysts publishing ratings: 10 Buy, 4 Hold, and 0 Sell, yielding a consensus recommendation of "buy" and a recommendation mean of 1.79 (where 1.0 is a strong buy). The average target price is $382.42, which implies roughly +6.5% upside from the current $359.03, a modest but positive expected return that suggests the stock has already captured much of the Street's near-term optimism after its sharp six-month run. Consensus leans clearly bullish on direction, but the limited upside to the average target indicates analysts see the stock as fairly valued to slightly undervalued rather than deeply discounted. The target range spans $330.00 to $414.00, a spread of about 25% of the current price, signaling meaningful but not extreme disagreement. The high target of $414.00 — roughly 15% above the average — likely assumes continued specialty-driven margin expansion, successful execution on the fiscal 2027 guidance, and possibly multiple re-rating as the market rewards higher-quality earnings; the low target of $330.00, about 8% below the current price, likely prices in margin compression, drug pricing pressure, or customer concentration risk. Institutional ratings show a stable-to-constructive pattern with no downgrades: JP Morgan, Morgan Stanley, Wells Fargo, and Evercore ISI all maintain Overweight or Outperform, UBS and Argus carry Buy, and RBC is the lone Sector Perform at neutral — recent actions are reiterations rather than upgrades, suggesting analysts are comfortable with existing theses rather than newly enthusiastic. The estimated EPS average of $31.66 and revenue average of $426.4 billion for the forward period underscore expectations for continued top-line scale and earnings delivery.
Bulls vs Bears: COR Investment Factors
The bull case currently has stronger evidence: margins are genuinely expanding (gross margin 4.08% vs 3.11% a year ago), free cash flow is robust at $3.88 billion TTM, the stock trades at 16.65x earnings versus a 27.60x historical PE at Q4 FY2026, and 10 of 12 analysts rate it Buy with no Sells. The bear case rests on structural fragility rather than deterioration — a 1.03% net margin, 3.06x debt-to-equity, a sub-1.0 current ratio, and lumpy earnings driven by other income items — plus the fact that only +6.5% upside remains to the average target after a 39.32% six-month rally. The single most important tension is whether specialty mix shift can sustainably hold gross margins near 4% or better; if margins revert toward the 3.1% level of prior-year Q4, the earnings compounding thesis collapses and the low multiple becomes deserved rather than a discount. Conversely, if FY2027 guidance is met with margins holding above 4%, the stock has room to re-rate toward the $414 high target.
Bullish
- Specialty-driven margin expansion is real: Q4 FY2026 gross margin rose to 4.08% from 3.11% a year earlier, and gross profit climbed to $3.60 billion from $2.60 billion, a ~38% increase on only 5.52% revenue growth. Q3 FY2026 was even stronger at a 4.26% gross margin with $763.5 million of net income, confirming the mix shift toward specialty and higher-margin adjacent services is translating into tangible profit leverage rather than a one-quarter anomaly.
- Cheap multiple versus own history: The trailing PE of 16.65x sits well below the 27.60x historical PE at fiscal Q4 2026 and the 17.91x at Q3, placing today's multiple in the lower-middle of its recent band despite improving profitability. The forward PE of 16.54x is nearly identical to trailing, meaning the market is not pricing in the EPS growth implied by the raised FY2026 guide and upbeat FY2027 outlook.
- Robust free cash flow and negative cash cycle: TTM free cash flow is $3.88 billion, with Q4 operating cash flow of $3.10 billion and FCF of $2.70 billion after $398 million of capex, comfortably covering $116 million of dividends and $481 million of debt repayment. A negative cash conversion cycle of -12.09 days means suppliers effectively fund the working capital, a structural advantage that supports the 0.82% dividend and buyback capacity.
- Analyst consensus firmly constructive: Of 12 analysts, 10 rate Buy and none rate Sell, producing a recommendation mean of 1.79 and a consensus 'buy'. The average target of $382.42 implies +6.5% upside, while the high target of $414.00 implies roughly +15%, and recent actions from JP Morgan, Morgan Stanley, Wells Fargo, and Evercore ISI are reiterations of Overweight/Outperform rather than downgrades.
Bearish
- Thin margins leave little error cushion: Net margin is just 1.03% and operating margin 1.16%, so a modest shift in generic pricing or specialty reimbursement could erase a large share of profit. Gross margin of 4.11% means a mere 41 basis points of gross-margin compression would wipe out roughly 10% of gross profit, an outsized sensitivity for a $88 billion quarterly revenue base.
- Leverage and weak liquidity metrics: Debt-to-equity stands at 3.06x and the current ratio is below 1.0 at 0.937, indicating limited short-term liquidity buffer. Interest coverage of 6.65x and a cash-flow-to-debt ratio of 0.275 are adequate but not lavish, and the 94.6% ROE is flattered by a very thin equity base rather than superior returns on capital.
- Earnings and cash flow are lumpy: Q2 FY2026 net income of $1.64 billion was boosted by $743.6 million of other income, while Q4 FY2025 posted a net loss of -$339.7 million driven by -$1.04 billion of other expenses. Q1 FY2026 operating cash flow was -$2.31 billion on a -$3.40 billion working-capital swing, so headline profitability and cash generation should be judged on a trailing basis rather than quarter to quarter.
- Limited upside to consensus target: The average target of $382.42 offers only +6.5% upside from $359.03 after a 39.32% six-month run, suggesting much of the near-term optimism is already priced in. The low target of $330.00 sits about 8% below the current price, and the 25%-of-price target spread signals genuine disagreement about margin durability.
COR Technical Analysis
Cencora is in a powerful, sustained uptrend that has carried shares from a 52-week low of $244.82 to a current price of $359.03, placing the stock at roughly 86% of its 52-week range (with a high of $377.54). Notably, the 1-year price change is -1.76%, meaning the trailing twelve-month return is still slightly negative even as the stock trades near the upper end of its range — a signature of a V-shaped recovery rather than a smooth advance, with the -32.56% max drawdown illustrating how sharp the prior decline was. This positioning signals momentum and improving conviction, but also leaves limited cushion to the prior high, making the $377.54 level the key test for continuation. Recent momentum is decisively positive and accelerating: the stock is up 6.80% over one month, 14.41% over three months, and 39.32% over six months, with a 5.95% YTD gain. The divergence between the negative 1-year return and the strong 3- and 6-month gains confirms the trend has inflected upward, and relative strength versus the S&P 500 is striking — +9.06 percentage points over one month, +17.24 over three months, and +37.19 over six months, against SPY moves of -2.26%, -2.83%, and +2.13% respectively. The one soft spot is the -14.03 percentage point 1-year relative strength, a reminder that the recovery is recent; the 2.76% single-day gain on the latest close suggests buyers remain aggressive near the highs. Key technical support sits at the $244.82 52-week low, with intermediate support likely in the $300-$310 zone where the stock consolidated in September and October; resistance is the $377.54 52-week high, and a breakout above it would confirm a new leg higher and likely trigger momentum-driven buying. A breakdown below $300 would signal the recovery is stalling and refocus attention on the low. Volatility is a relative advantage here: beta of 0.571 means the stock is roughly 43% less volatile than the market, supporting larger position sizing for risk-adjusted investors, while the 2.61 short ratio indicates short interest is modest and not a meaningful squeeze or overhang factor.
Beta
0.57
0.57x market volatility
Max Drawdown
-32.6%
Largest decline past year
52-Week Range
$245-$378
Price range past year
Annual Return
-1.4%
Cumulative gain past year
| Period | COR Return | S&P 500 |
|---|---|---|
| 1m | +4.7% | -3.0% |
| 3m | +12.9% | -3.6% |
| 6m | +34.8% | -0.2% |
| 1y | -1.4% | +10.1% |
| ytd | +5.3% | +8.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
COR Fundamental Analysis
Revenue is growing steadily rather than spectacularly, consistent with the wholesale model: fiscal Q4 2026 revenue reached $88.35 billion with 5.52% year-over-year growth, up from $83.73 billion in the prior-year Q4. The multi-quarter trend shows consistent expansion — $85.93 billion in Q1, $78.36 billion in Q2, $84.75 billion in Q3, and $88.35 billion in Q4 — with the Q2 dip reflecting normal seasonality rather than deterioration. Segment data shows U.S. Healthcare Solutions at $74.86 billion dominates the mix, with International Healthcare Solutions at $7.68 billion and Other at $2.25 billion, meaning growth is primarily driven by the domestic specialty franchise while international provides a smaller but strategically valuable diversification lever. The trajectory supports the thesis that specialty mix, not raw volume, is the growth engine. Profitability is thin but improving, which is the crux of the investment case: Q4 net income was $519.4 million on a 4.08% gross margin and 1.03% operating margin, with net margin of just 1.03%. Margins have expanded meaningfully year over year — gross margin rose from 3.11% in the prior-year Q4 to 4.08%, and operating margin from 1.02% to 1.03% — while the prior-year Q4 posted a net loss of -$339.7 million, making the swing to $519.4 million profit a dramatic turnaround. Q3 2026 was even stronger at $763.5 million net income and a 4.26% gross margin, and Q2 delivered $1.64 billion net income aided by other income, showing the business can generate outsized profit when specialty and other income items cooperate. For a distributor, sub-5% gross margins are normal, so the key signal is direction, and direction is favorable. Balance sheet and cash flow present a mixed but manageable picture: debt-to-equity is high at 3.06x, the current ratio is below 1.0 at 0.937, and ROE is an extraordinary 94.6% — inflated by a very thin equity base typical of distributors. Free cash flow is robust at $3.88 billion TTM, with Q4 operating cash flow of $3.10 billion and FCF of $2.70 billion after $398 million of capex, comfortably covering $116 million of dividends and $481 million of debt repayment. The cash conversion cycle is negative at -12.09 days, meaning the company funds operations with supplier credit rather than its own capital — a structural advantage — while interest coverage of 6.65x and a 0.275 cash-flow-to-debt ratio indicate adequate but not lavish debt service capacity. The main caveat is working-capital volatility: Q1 FY2026 saw -$2.31 billion operating cash flow on a -$3.40 billion working-capital swing, so cash generation is lumpy and should be judged on a trailing basis.
Quarterly Revenue
$88.4B
2026-09
Revenue YoY Growth
+5.5%
YoY Comparison
Gross Margin
4.1%
Latest Quarter
Free Cash Flow
$3.9B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is COR Overvalued?
Because Cencora is solidly profitable — Q4 net income of $519.4 million and positive TTM earnings — the PE ratio is the appropriate primary metric, and it paints a compelling picture: trailing PE of 16.65x against a forward PE of 16.54x, an unusually narrow gap that implies the market is not pricing in aggressive near-term earnings acceleration. The PEG ratio of 0.133 is extraordinarily low, suggesting earnings growth is vastly outpacing the multiple, though this figure should be treated cautiously given the earnings volatility from the prior-year loss. The low absolute multiple reflects the market's structural discount for thin-margin distribution businesses. On peer comparison, the valuation data provided does not include explicit industry average multiples, so a precise quantified spread cannot be stated; however, the internal metrics are revealing — PS ratio of 0.172 and EV/Sales of 0.222 are characteristic of high-volume, low-margin distributors, while EV/EBITDA of 10.53x and PCF of 12.11x sit in a reasonable range for the sector. The 15.76x price-to-book ratio looks extreme but is an artifact of the company's minimal book equity rather than a genuine premium, and the 0.82% dividend yield with a conservative 13.7% payout ratio leaves ample room for continued capital return. Against its own history, the stock looks inexpensive on earnings: the historical PE ratio was 27.60x at fiscal Q4 2026, 17.91x at Q3, and 9.31x at Q2, versus the current 16.65x, placing today's multiple in the lower-middle of its recent band. The historical PS ratio of 0.648 at Q4 2026 compares with the current 0.172, though methodology differences between the datasets caution against over-reading that gap. Net-net, the market is pricing Cencora at a modest earnings multiple despite improving margins and specialty-driven growth, implying either a value opportunity or lingering skepticism about the durability of margin gains.
PE
16.7x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 9x~29x
vs. Industry Avg
26.2x
Industry PE ~26.2x*
EV/EBITDA
10.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the extreme thinness of the margin structure and the leverage beneath it. Net margin of 1.03% and operating margin of 1.16% mean that a 41-basis-point compression in the 4.11% gross margin would eliminate roughly a tenth of gross profit, and generic drug deflation or specialty reimbursement pressure could easily produce that. Debt-to-equity of 3.06x with a current ratio of 0.937 leaves limited liquidity cushion, and interest coverage of 6.65x means a higher rate environment would bite into already narrow earnings. Earnings quality is also uneven: Q2 FY2026's $1.64 billion net income included $743.6 million of other income, while Q4 FY2025 swung to a -$339.7 million loss on -$1.04 billion of other expenses, and Q1 FY2026 operating cash flow was -$2.31 billion on a -$3.40 billion working-capital swing — so both earnings and cash generation are lumpier than the trailing figures imply.
Market and competitive risks are dominated by valuation compression and the structural discount applied to distributors. At 16.65x trailing earnings the stock is not expensive in absolute terms, but the market has historically paid 27.60x at Q4 FY2026 and 17.91x at Q3, so a reversion toward the low end of that band is a real possibility if margin gains stall; the +6.5% upside to the $382.42 average target leaves little cushion. Beta of 0.571 provides meaningful insulation from broad market drawdowns, but the trailing one-year return of -1.76% against SPY's +12.27% shows the stock can lag badly during sector rotation even while its six-month relative strength is +37.19 points. Competitive pressure comes from McKesson and Cardinal Health in an oligopoly where share shifts are won on price and service, and drug pricing policy — manufacturer rebate reform or PBM transparency rules — could compress the economics of the specialty and commercialization businesses that are driving the margin story.
A worst-case scenario would combine a specialty margin reversal with a major customer loss and a policy shock: gross margin sliding back toward the 3.1% prior-year level, a large retail pharmacy chain renegotiating or shifting volume, and drug pricing legislation hitting manufacturer services simultaneously. In that chain of events, the earnings compounding thesis breaks, the multiple would likely compress toward the low end of its historical band, and the stock could retest the $244.82 52-week low — roughly -32% from the current $359.03, consistent with the -32.56% max drawdown already experienced. Even a milder adverse case aligning with the $330.00 analyst low target implies about -8% downside, so the realistic loss range in a bad scenario is -8% to -32%, with the deeper end requiring margin reversion plus a customer or policy shock.
FAQ
From a risk/reward standpoint COR is a reasonable but not exceptional buy: the average analyst target of $382.42 implies about +6.5% upside from $359.03, while the $330.00 low target implies roughly -8% downside, a positive but not asymmetric setup. The valuation support is real — 16.65x trailing and 16.54x forward earnings versus a 27.60x historical PE at Q4 FY2026 — and the business is generating $3.88 billion of TTM free cash flow with a negative -12.09 day cash conversion cycle. The biggest downside risk is gross-margin reversion toward the 3.11% prior-year Q4 level, which would undermine the earnings-compounding thesis and could send shares toward the $244.82 52-week low in a severe case. It is best suited to conservative investors who value beta of 0.571, a 0.82% dividend, and 10 of 12 analysts rating Buy with zero Sells, and who can tolerate modest near-term upside after the 39.32% six-month run. More aggressive buyers may prefer to wait for a pullback toward the $330-$340 zone or for confirmation that gross margin holds above 4.2%.

